高用量の純粋な魚油ベースの脂肪エムルションを受けた小児患者の治療結果: 遡及的研究
Anam Bashir1, Lauren Karel2, Meg Begany3
1Division of Gastroenterology, Hepatology, and Nutrition, Children's Hospital of Philadelphia, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
まとめ
魚油ベースの脂肪エムルション (FO-ILE) の高用量投与は,小児患者の体重増加を改善し,デクストロースの必要性を減少させる可能性があります. この研究は,FO-ILEの増加が安全で有益であることを示唆し,さらなる調査を正当化しています.
科学分野:
- 小児胃腸内科
- パレンタル栄養
- 肝臓の代謝
背景:
- 魚油ベースの脂質乳液 (FO-ILE) は,腸機能不全に関連する肝疾患に対して1g/kg/日でFDAによって承認されています.
- より高い用量は改善する可能性があるが,特に新生児では十分なデータがない.
- この研究では,小児患者の高いFO-ILE用量 (1.5g/kg/日) を評価した.
研究 の 目的:
- 小児患者におけるFO- ILEの投与量増加 (1. 5g/ kg/ 日) の安全性と有効性を評価する.
- 体重増加とグルコース注入率 (GIR) に関するより高いFO-ILE用量の影響を評価する.
- FO-ILEの高用量に関連した潜在的な有害効果を特定する.
主な方法:
- 少なくとも14日間,FO-ILEを1.5g/ kg/ 日で親腸経由で摂取した小児患者 (0~18歳) の逆行図の見直し.
- 分析された臨床アウトカムには,体重増加,GIR,および有害事象 (コレスタシス,出血,高トリグリセリデミア,EFA欠乏症) が含まれていた.
主要な成果:
- 9人の患者のうち7人が体重増加を示した.
- 4人の患者はGIRの減少を経験しました.
- 一人の患者にはコレスタシスがあり,投与量を下げると回復し,高トリグリセリデミアまたはEFA欠乏症は観察されなかった.
結論:
- FO- ILEの投与量の増加 (1. 5g/ kg/ 日) は,体重増加とGIRの上昇を伴う小児患者にとって安全で潜在的に有益である.
- これらの発見を確認するために,さらなる大規模な長期的な研究が必要である.
関連する概念動画
01:15Bioavailability Study Design: Healthy Subjects Versus Patients
73
Bioavailability studies are essential for evaluating a drug's therapeutic efficacy and understanding its absorption patterns under various physiological conditions. Conducting such studies on target patient populations provides more relevant data by simulating real-world disease states. However, practical challenges often necessitate the use of young, healthy adult volunteers as study subjects.Patients may exhibit altered drug absorption patterns due to the effects of the disease itself,...
73
01:23Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption
155
Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
155
01:17Pharmacokinetics in Pediatric Patients: Drug Distribution
180
Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
180
01:24Pharmacokinetics in Pediatric Patients: Drug Metabolism
117
In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
117
01:26Pharmacokinetics in Pediatric Patients: Drug Excretion
138
In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
138